Clinical Trials on Refractory Breast Carcinoma in Germany

Total 2233 results

Ludwig-Maximilians - University of Munich
Pierre Fabre Laboratories

Completed

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Carcinoma Breast Stage IV

Germany
University Hospital Tuebingen

Recruiting

Postoperative Pain After Breast Surgery Under Tumescent Local Anaesthesia Versus General Anaesthesia ( TLA-001 )

Breast Carcinoma | Breast Carcinoma in Situ

Germany
SamanTree Medical SA
St. Vincenz Krankenhaus GmbH, Paderborn

Completed

Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment (SHIELD)

Breast-Conserving Surgery | Breast Cancer - Ductal Carcinoma in Situ (DCIS)

Germany
German Breast Group
Celgene Corporation; Amgen

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
German Breast Group
Roche Pharma AG; Celgene Corporation

Completed

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
German Breast Group

Completed

Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast (ICE-II)

Breast Cancer

Germany
German Breast Group
Roche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor Pharma

Completed

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Pierre Fabre Pharma GmbH
iOMEDICO AG

Completed

Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer | Non Small Cell Lung Carcinoma

Germany
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer (CLEAR-B)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Germany
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
University of Magdeburg
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) and Vinorelbine

Carcinoma Breast Stage IV

Germany
AIO-Studien-gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

Chemo-refractory Colorectal Carcinoma

Germany
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
Fondazione Michelangelo

Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)

Invasive Ductal Breast Carcinoma

Spain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
Kliniken Essen-Mitte
German Breast Group

Completed

Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer

Early-Stage Breast Carcinoma

Germany, Switzerland
University of Jena
University Hospital Erlangen; Labor Prof. Pachmann

Recruiting

Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age. (CETC)

Tumor Cell, Circulating

Germany
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Hannover Medical School
University Hospital, Ghent; Johann Wolfgang Goethe University Hospital; University... and other collaborators

Unknown

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

De Novo Akute Myeloid Leukemia (AML) | Secondary Acute Myeloid Leukemia (AML) | Refractory Anemia With Excess of Blasts in Transformation

Germany
University Hospital Schleswig-Holstein
University of Luebeck

Active, not recruiting

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer (HYPOSIB)

Early-Stage Breast Carcinoma

Germany
AstraZeneca
German Adjuvant Breast Cancer Group

Completed

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. (ARNO-95)

Breast Cancer

Germany
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
Immutep S.A.S.

Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Adenocarcinoma Breast Stage IV

Netherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
Palleos Healthcare GmbH
Roche Pharma AG; University Hospital, Essen; University Hospital Erlangen; Phaon...

Active, not recruiting

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)

Triple-negative Breast Cancer

Germany
University of Leipzig

Completed

Renal Sympathetic Denervation in Mild Refractory Hypertension

Refractory Hypertension

Germany
West German Study Group
Celgene

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

Breast Cancer

Germany
University Hospital Tuebingen
University Hospital Freiburg; University Hospital Ulm

Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

Germany
photonamic GmbH & Co. KG

Terminated

Fluorescence-guided Resection in Breast Cancer

Breast Tumour

Germany
German Breast Group

Completed

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Primary Breast Cancer

Germany
German Breast Group

Terminated

Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

Metastatic Breast Cancer

Germany
AIO-Studien-gGmbH
Novartis Pharmaceuticals; iOMEDICO AG

Completed

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (VicTORia)

Her2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast Cancer

Germany
Universitätsklinikum Hamburg-Eppendorf

Completed

Esophagogastrectomy Versus Extended Gastrectomy in AEG II (AEG-II-EG)

Carcinomas of the Esophagogastric Junction

Germany
Technical University of Munich
Eli Lilly and Company

Recruiting

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients (Abemacare)

Breast Cancer/ Metastatic Breast Cancer

Germany
Shenzhen Core Medical Technology CO.,LTD.

Not yet recruiting

Corheart 6 VAS Study

Refractory Heart Failure

Germany
German Breast Group
Boehringer Ingelheim

Completed

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy (DAFNE)

Unilateral HER2 Positive Breast Cancer

Germany
German Breast Group

Completed

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA)

Breast Cancer Metastatic

Germany
University of Jena

Completed

Analysis of Circulating Epithelial Tumor Cells in Peripheral Blood in Patients With Primary Non-metastatic Breast Cancer Under Adjuvant Radiotherapy

Breast Cancer Female

Germany
iOMEDICO AG
Roche Pharma AG; Arbeitsgemeinschaft fur Internistische Onkologie; Arbeitskreis...

Completed

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer (CARIN)

Metastatic Breast Cancer

Germany
Novartis

Completed

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Metastatic Breast Cancer

Germany
West German Study Group
Sanofi; Amgen

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing

Germany
Kliniken Essen-Mitte

Recruiting

Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy (Ultra3Detect)

Primary Breast Cancer

Germany
Prof. Wolfgang Janni
Roche Pharma AG; Novartis Pharmaceuticals; Celgene Corporation; Eisai GmbH

Active, not recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Metastatic Breast Cancer

Germany
University Hospital Tuebingen
Paul Ehrlich Institute, Langen, Germany

Completed

Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) (KS2422-vacc)

Metastatic Breast Cancer

Germany
Kliniken Essen-Mitte

Recruiting

TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes (SenTa2)

Breast Cancer | Node-positive Breast Cancer

Germany
RWTH Aachen University
Univ.-Prof. Dr. med. F. Kiessling

Unknown

KVUS at Neoadjuvant CTx of Breast Cancer

Early Primary Breast Cancer

Germany
Novartis Pharmaceuticals
Roche - Prof. Dr. Jens Huober et al.

Terminated

Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer (eLEcTRA)

Metastatic Breast Cancer

Germany
German Breast Group
Pfizer

Completed

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (MALE)

Male Breast Cancer

Germany
RWTH Aachen University

Recruiting

mULM to Support Breast Cancer Diagnosis and Therapy

Primary Breast Cancer

Germany
German Breast Group
AstraZeneca; Celgene

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer

Germany
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany

Clinical Trials on Refractory Breast Carcinoma in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations